Securities Code: 300181
Securities Abbreviation: ZL Pharma
Announcement No.: 2026-42
Zhejiang ZL Pharma Co., Ltd.
Resolution Announcement of the 16th Extraordinary (Ad Hoc) Meeting of the 8th Board of Directors
The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and are free from false records, misleading statements, or major omissions.
I. Convening of the Board Meeting
The 16th Extraordinary (Ad Hoc) Meeting of the 8th Board of Directors of Zhejiang ZL Pharma Co., Ltd. (hereinafter referred to as the "Company") was held on June 23, 2026, at the Company's meeting room, combining on-site and teleconference methods. This meeting was an urgent ad hoc meeting. With the unanimous consent of all directors, the notice period requirement for this meeting was waived. The meeting notice was delivered to all directors on June 22, 2026, through a combination of personal delivery, telephone, fax, and email. A total of 9 directors were eligible to attend, and 9 directors attended (including Director Wang Tao, Independent Directors Zhu Jian, and Wang Ping who participated via written voting). The meeting was chaired by Mr. Yu Youqiang, Chairman of the Company. Company senior management attended the meeting. Chairman Yu Youqiang explained the reasons for the urgent meeting. The convening of the meeting complies with the "Company Law of the People's Republic of China" and the "Articles of Association" of the Company.
II. Deliberation of the Board Meeting
- Deliberation and Approval of the "Proposal on Adjusting the Company's Plan for Issuing Convertible Bonds to Non-specific Targets"
To ensure the smooth progress of the Company's issuance of convertible bonds to non-specific targets, and based on the authorization granted by the second extraordinary general meeting of shareholders in 2025, the Company has adjusted the total amount of funds to be raised from the issuance of convertible bonds to non-specific targets. The specific details are as follows:
(1) Issuance Scale
Before adjustment:
In accordance with relevant laws and regulations and combined with the Company's financial situation and investment plan, the total amount of funds to be raised from the proposed issuance of convertible bonds shall not exceed RMB 152,312.03 million (inclusive). The specific amount shall be determined by the Company's shareholders' meeting authorizing the Company's board of directors or its authorized personnel within the aforementioned limit.